680 related articles for article (PubMed ID: 28944771)
1. The spectrum of T cell metabolism in health and disease.
Bantug GR; Galluzzi L; Kroemer G; Hess C
Nat Rev Immunol; 2018 Jan; 18(1):19-34. PubMed ID: 28944771
[TBL] [Abstract][Full Text] [Related]
2. Cellular metabolism dictates T cell effector function in health and disease.
Kolan SS; Li G; Wik JA; Malachin G; Guo S; Kolan P; Skålhegg BS
Scand J Immunol; 2020 Nov; 92(5):e12956. PubMed ID: 32767795
[TBL] [Abstract][Full Text] [Related]
3. T-cell immunometabolism against cancer.
Jiang S; Yan W
Cancer Lett; 2016 Nov; 382(2):255-258. PubMed ID: 27664755
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Barriers to T Cell Function in Tumors.
Sugiura A; Rathmell JC
J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
[TBL] [Abstract][Full Text] [Related]
5. Emerging concepts of T cell metabolism as a target of immunotherapy.
Chang CH; Pearce EL
Nat Immunol; 2016 Apr; 17(4):364-8. PubMed ID: 27002844
[TBL] [Abstract][Full Text] [Related]
6. The role of T cells in the microenvironment of Hodgkin lymphoma.
Wein F; Küppers R
J Leukoc Biol; 2016 Jan; 99(1):45-50. PubMed ID: 26320264
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.
Welters MJP; Ma W; Santegoets SJAM; Goedemans R; Ehsan I; Jordanova ES; van Ham VJ; van Unen V; Koning F; van Egmond SI; Charoentong P; Trajanoski Z; van der Velden LA; van der Burg SH
Clin Cancer Res; 2018 Feb; 24(3):634-647. PubMed ID: 29018052
[No Abstract] [Full Text] [Related]
8. Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.
Allison KE; Coomber BL; Bridle BW
Immunology; 2017 Oct; 152(2):175-184. PubMed ID: 28621843
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells in cancer; can they be controlled?
Adeegbe DO; Nishikawa H
Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166
[No Abstract] [Full Text] [Related]
10. Nutrients and the microenvironment to feed a T cell army.
Johnson MO; Siska PJ; Contreras DC; Rathmell JC
Semin Immunol; 2016 Oct; 28(5):505-513. PubMed ID: 27712958
[TBL] [Abstract][Full Text] [Related]
11. Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.
Ho PC; Kaech SM
Curr Opin Immunol; 2017 Jun; 46():38-44. PubMed ID: 28458087
[TBL] [Abstract][Full Text] [Related]
12. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
13. Targeting T cell metabolism for therapy.
O'Sullivan D; Pearce EL
Trends Immunol; 2015 Feb; 36(2):71-80. PubMed ID: 25601541
[TBL] [Abstract][Full Text] [Related]
14. The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses.
Aptsiauri N; Ruiz-Cabello F; Garrido F
Curr Opin Immunol; 2018 Apr; 51():123-132. PubMed ID: 29567511
[TBL] [Abstract][Full Text] [Related]
15. Skewed T-cell receptor repertoire: more than a marker of malignancy, a tool to dissect the immunopathology of inflammatory diseases.
Pandolfi F; Cianci R; Casciano F; Pagliari D; De Pasquale T; Landolfi R; Di Sante G; Kurnick JT; Ria F
J Biol Regul Homeost Agents; 2011; 25(2):153-61. PubMed ID: 21880203
[TBL] [Abstract][Full Text] [Related]
16. [Metabolic Competition in Tumor Microenvironment].
Eikawa S; Udono H
Gan To Kagaku Ryoho; 2017 Nov; 44(11):972-976. PubMed ID: 29138369
[TBL] [Abstract][Full Text] [Related]
17. B cells, plasma cells and antibody repertoires in the tumour microenvironment.
Sharonov GV; Serebrovskaya EO; Yuzhakova DV; Britanova OV; Chudakov DM
Nat Rev Immunol; 2020 May; 20(5):294-307. PubMed ID: 31988391
[TBL] [Abstract][Full Text] [Related]
18. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
[TBL] [Abstract][Full Text] [Related]
19. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
20. Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover.
Krejsgaard T; Lindahl LM; Mongan NP; Wasik MA; Litvinov IV; Iversen L; Langhoff E; Woetmann A; Odum N
Semin Immunopathol; 2017 Apr; 39(3):269-282. PubMed ID: 27717961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
